Article
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
The New England journal of medicine - 31 Dec 2015
Foster Graham R, Afdhal Nezam, Roberts Stuart K, Bräu Norbert, Gane Edward J, Pianko Stephen, Lawitz Eric, Thompson Alex, Shiffman Mitchell L, Cooper Curtis, Towner William J, Conway Brian, Ruane Peter, Bourlière Marc, Asselah Tarik, Berg Thomas, Zeuzem Stefan, Rosenberg William, Agarwal Kosh, Stedman Catherine A M, Mo Hongmei, Dvory-Sobol Hadas, Han Lingling, Wang Jing, McNally John, Osinusi Anu, Brainard Diana M, McHutchison John G, Mazzotta Francesco, Tran Tram T, Gordon Stuart C, Patel Keyur, Reau Nancy, Mangia Alessandra, Sulkowski Mark
Abstract excerpt
BACKGROUND: In phase 2 trials, treatment with the combination of the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir resulted in high rates of sustained virologic response in patients chronically infected with hepatitis C virus (HCV) genotype 2 or 3. METHODS: We conducted two randomized, phase 3, open-label studies involving patients who had received previous treatment for HCV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.